Article
Maribavir use in practice for cytomegalovirus infection in French transplantation centers.
Transplantation proceedings - 1 May 2013
Alain S, Revest M, Veyer D, Essig M, Rerolles J P, Rawlinson W, Mengelle C, Huynh A, Kamar N, Garrigue I, Kaminski H, Segard C, Presne C, Mazeron M C, Avettant-Fenoël V, Lecuit M, Lortholary O, Coaquette A, Hantz S, Leruez-Ville M, Ploy M-C
Abstract excerpt
Maribavir (MBV), a UL97 inhibitor, shows good oral bioavailability, low host cell toxicity, and theoretical benefits to inhibit cross-resistant viruses. We herein examined clinical and virological outcomes of 12 patients, including 3 bone marrow recipients and 9 organ recipients infected with resistant cytomegalovirus (CMV) and treated with MBV during 2011-2012. All received at least 800-mg daily doses. They had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.